Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C152237
http://purl.obolibrary.org/obo/NCIT_C152237
|
|---|---|
| Preferred Name | Rivoceranib |
| Definitions |
An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. |
|---|---|
| prefLabel | Rivoceranib
|
| label | Rivoceranib
|
| Has_Salt_Form | |
| NCI_META_CUI | CL553441
|
| code | C152237
|
| Has_Target | |
| prefixIRI | NCIT:C152237
|
| in_subset | |
| Display_Name | Rivoceranib
|
| Preferred_Name | Rivoceranib
|
| FDA_UNII_Code | 5S371K6132
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Rivoceranib
|
| CAS_Registry | 811803-05-1
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |